Comparative Pharmacology
Head-to-head clinical analysis: NEPHROSCAN versus TECHNESCAN MAG3.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEPHROSCAN versus TECHNESCAN MAG3.
NEPHROSCAN vs TECHNESCAN MAG3
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Calcium trisodium pentetate (NEPHROSCAN) chelates gadolinium ions by forming a stable complex with the metal, thereby reducing the toxicity and enhancing elimination of gadolinium from the body. It acts as a decorporation agent for gadolinium.
TECHNESCAN MAG3 (mertiatide) is a radiopharmaceutical that undergoes renal tubular secretion via the organic anion transporter (OAT) system, allowing dynamic imaging of renal perfusion and function. After intravenous administration, it exhibits rapid clearance from the blood by the kidneys, providing assessment of effective renal plasma flow.
1 to 5 mCi (37 to 185 MBq) as a single intravenous injection for renal imaging.
185-370 MBq (5-10 mCi) intravenous bolus injection for renal imaging.
None Documented
None Documented
Terminal elimination half-life: 1.6 hours in normal renal function; prolonged to >20 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life: approximately 2.5 hours in patients with normal renal function; prolonged in renal impairment.
Renal: 95% as unchanged drug via glomerular filtration; no biliary/fecal excretion.
Renal: approximately 90% of injected dose excreted by glomerular filtration and tubular secretion within 24 hours; biliary/fecal: <1%.
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical